Rheumatology key messagesPolymyalgia-rheumatica and rheumatoid-arthritis-like syndromes are frequent with checkpoint inhibitors therapy.Myositis is a potentially life-threatening complication.Other systemic manifestations, including sicca syndrome, vasculitis, sarcoidosis, systemic sclerosis and lupus, are described.

Introduction
============

Although the concept of immunotherapy in cancer is far from new, the monoclonal antibodies 'checkpoint inhibitors' (CPI) targeting CTLA-4 or PD-1/PD-L1 pathway clearly marked a turning point in the success of this approach \[[@kez295-B1]\]. By enhancing antitumour T-cell activity, some unprecedented long-lasting tumour responses were observed in patients with unresectable or metastatic disease \[[@kez295-B2]\]. The clinical value of these CPI, as single agent or in combination, is being investigated in various solid tumours and hematological malignancies, and their use is expanding rapidly. As anticipated, the T-cell activation induced by such therapies promotes inflammatory side effects, known as immune-related adverse events (irAEs). Compared with conventional cancer therapies, this spectrum of toxicities is unique and can affect any organ system, with a particular tropism for the gastrointestinal tract, endocrine glands, skin and liver \[[@kez295-B3]\]. Arthralgia and myalgia were by far the most commonly reported rheumatic irAEs in clinical trials, with a prevalence ranging from 1% to 43% and from 2% to 21%, respectively \[[@kez295-B4]\]. To date, a growing number of case series and reports is describing clinical features of *de novo* rheumatic irAEs, which will be the focus of this review. Of note, some of them have the appearance of classic rheumatic and musculoskeletal diseases (RMDs) and others mimic RMDs, therefore representing potentially new clinical variants.

Rheumatic manifestations
========================

While the two major clinical entities observed are PMR-like syndromes \[[@kez295-B5]\] and RA-like syndromes \[[@kez295-B8]\], the broad spectrum of rheumatic irAEs includes arthralgia \[[@kez295-B11]\], monoarthritis and oligoarthritis \[[@kez295-B12]\], polyarthritis \[[@kez295-B13], [@kez295-B14]\], PsA \[[@kez295-B15]\], reactive arthritis \[[@kez295-B8]\], RS3PE \[[@kez295-B18]\], tenosynovitis \[[@kez295-B21]\], enthesitis \[[@kez295-B22]\], non-inflammatory musculoskeletal conditions \[[@kez295-B6]\] and osteoarthritis \[[@kez295-B11]\]. These are all the clinical patterns found in the literature regarding rheumatic irAEs, in addition to arthritis or inflammatory arthritis, which are the terms often used \[[@kez295-B8], [@kez295-B23], [@kez295-B24]\].

The joints involved most frequently are the shoulders, MCP and PIP joints of the hands (around 50%), followed by the knees and wrists (40%). The hips, elbows, ankles and feet are also affected in some patients, as described in [Fig. 1](#kez295-F1){ref-type="fig"} (unpublished personal data).

![Frequency and type of joints involvement in patients experiencing rheumatic irAEs with CPI therapy CPI: checkpoint inhibitors; irAEs: immune-related adverse events.](kez295f1){#kez295-F1}

Except for osteoarthritis cases, synovial fluid analysis revealed a clear inflammatory reaction with predominant polymorphonuclear cells \[[@kez295-B23], [@kez295-B25], [@kez295-B26]\] but lymphocytic component is also described \[[@kez295-B27]\]. When reported, inflammatory markers are elevated for two-thirds of patients with a median CRP value of 58 mg/l (from 6 to 332 mg/l). Importantly, the search for antibodies is negative for a large proportion of patients or with isolated ANA positivity \>1/160. This striking preponderance of seronegative diseases is observed by several groups, which is an important message for clinicians \[[@kez295-B4], [@kez295-B10], [@kez295-B23], [@kez295-B24]\]. Indeed, only a few patients are tested positive for RF and/or anti-CCP antibodies \[[@kez295-B28]\]. Plain radiographs are inconsistently reported and often considered as normal, but osteoarthritis lesions, joint space narrowing and erosions may be visualized \[[@kez295-B23], [@kez295-B29]\]. Ultrasound data available in the literature include mostly the presence of synovitis (31%), tenosynovitis (24%) or bursitis (15%), also frequently reported with PET-CT or MRI, as illustrated in [Fig. 2](#kez295-F2){ref-type="fig"}.

![CPI-induced tenosynovitis(**A**) Clinical presentation and (**B**) MRI findings on T1-SPIR weighted sequence with gadolinium-enhanced tenosynovitis. CPI: checkpoint inhibitors; SPIR: spectral presaturation with inversion recovery.](kez295f2){#kez295-F2}

Overall, on the basis of case series and case reports, around 20% of patients fulfilled classification criteria of RA (55/271) or PMR (11/52). This percentage is higher (55%) for PsA (6/11). Rheumatologists should be aware that patients might present with atypical features, such as PMR clinical phenotype with no increase of inflammatory markers or RA-like symptoms without autoantibodies.

Myositis
========

Several cases of myositis have been reported as a potentially life-threatening complication in patients treated with CPI, presenting with remarkably homogeneous and unique clinicopathologic features ([Fig. 3](#kez295-F3){ref-type="fig"}) \[[@kez295-B30]\]. Symptoms onset is dominated by acute or subacute myalgia (38%) and proximal muscle weakness (50%) including some patients presenting with dropped head syndrome. Furthermore, up to 25% of patients may present with oculomotor (ptosis/diplopia) and/or bulbar (dysphagia/dysarthria) symptoms. Dyspnoea should alert on a possible concurrent myocarditis, which is frequently reported as critical complication \[[@kez295-B33]\]. Therefore, cardiac evaluation is needed in all patients presenting with CPI-induced myositis, including troponin, electrocardiography and echocardiogram if myocarditis is suspected. Associated myasthenia gravis is also frequently encountered (15%) and should be considered with weakness, diplopia or bulbar symptoms \[[@kez295-B32], [@kez295-B34], [@kez295-B35]\]. Most described cases have been associated with the presence of anti-acetylcholine receptor antibodies and decremental response was sometimes found on electromyogram. Finally, fatigue is reported in 7% of patients presenting with myositis and typical skin rash of dermatomyositis is described in few patients \[[@kez295-B36], [@kez295-B37]\].

![Distribution of muscle involvement in patients experiencing CPI-induced myositis: limb-girdle, cervical, eyes and heartCPI: checkpoint inhibitors.](kez295f3){#kez295-F3}

A strong increase in creatine kinase levels is reported in almost all patients presenting with myositis, with a median of 2650 UI/l (ranging from 335 to 20 270 UI/l). Of note, creatine kinase levels are usually within the normal range in patients presenting with myalgia \[[@kez295-B32], [@kez295-B38]\]. Myositis-associated autoantibodies are mostly negative, with the exception of rare case reports with positive ANA, anti-striated antibodies, anti-PM/Scl, anti-SM, anti-TIF1gamma, aPL-7, aPL12, anti-Jo1 or anti-signal recognition part \[[@kez295-B24], [@kez295-B32], [@kez295-B39], [@kez295-B40]\]. Of interest, anti-acetylcholine receptor and anti-striated muscle antibodies were detected in serum samples obtained prior to CPI therapy and associated with the development of myositis in thymoma patients \[[@kez295-B41]\]. Myopathic pattern is usually found on electrodiagnostic studies and musculature enhancement observed on MRI. Fasciitis is also reported on MRI findings \[[@kez295-B23], [@kez295-B42], [@kez295-B43]\]. Skeletal muscle biopsy is often performed and reveals variable degrees of inflammatory and necrotic changes \[[@kez295-B30]\].

Importantly, because of the frequent limb-girdle myalgia and weakness that may mimic PMR-like conditions, a high index of myositis suspicion is needed among rheumatologists with a low threshold for creatine kinase dosage in the diagnostic work-up of rheumatic irAEs. Furthermore, it is noteworthy to mention that median exposure time to CPI is usually shorter for myositis than for other rheumatic irAEs, with symptoms' onset occurring during the first month of treatment in half of the cases.

Sicca syndrome
==============

Clinical characteristics of sicca syndrome described with CPI include mostly dry mouth, in almost 80%, dry eyes being reported in half of cases and associated arthralgia in around 10% \[[@kez295-B5], [@kez295-B7], [@kez295-B8], [@kez295-B10], [@kez295-B44]\]. Parotid swelling and painful parotid gland are both reported in one patient and neurological symptoms occurred in three patients (two with paresthaesia, one reported as neuro-Sjögren) \[[@kez295-B47]\]. Of note, severe salivary hypofunction was documented by scintigraphy in two cases \[[@kez295-B10]\].

Only one case report mentioned a hypergammaglobulinaemia and one a normal serum protein electrophoresis; the data is missing for the others. Some, but not all, patients tested positive for ANA, SSA and/or SSB and/or RF.

The largest series including histopathological data of 20 patients experiencing sicca syndrome related to ICI has been published recently \[[@kez295-B48]\]. Interestingly, it showed a predominant T-cell infiltrate, composed mainly of CD3^+^ T cells with a slight predominance of CD4^+^ over CD8^+^ T cells, distinct from what is observed in classical Sjögren's syndrome with mainly CD20^+^ B cells and variable germinal centre formation.

Vasculitis
==========

Patients experiencing CPI-induced vasculitis presented with various clinical manifestations, including arthralgia, arthritis, myalgia, purpura, digital necrosis, fever, fatigue and abdominal pain. The corresponding diagnosis are cutaneous leucocytoclastic vasculitis \[[@kez295-B49]\], acral vasculitis \[[@kez295-B10], [@kez295-B50], [@kez295-B51]\], granulomatosis with polyangiitis \[[@kez295-B52]\], eosinophilic granulomatosis with polyangiitis \[[@kez295-B53]\], cryoglobulinemic vasculitis \[[@kez295-B44]\], giant cell arthritis \[[@kez295-B54]\] and a large proportion of cases are reported as vasculitis \[[@kez295-B7], [@kez295-B57], [@kez295-B58]\].

Acute phase reactants accompany symptoms' onset in one-third of patients. The search for ANA, ANCA, cryoglobulin and RF is often requested but rarely positive. Whenever possible, biopsy (i.e. skin, temporal artery) is performed and was contributive in all but one case.

Other systemic manifestations
=============================

In the last two years, the broad spectrum of irAEs is rapidly expanding, with descriptions of other various systemic manifestations.

Sarcoidosis or sarcoid-like reactions are commonly described \[[@kez295-B59], [@kez295-B60]\]. Up to 25% of patients might be asymptomatic, the diagnosis being suspected on imaging (usually PET-CT with new hilar lymphadenopathy or pulmonary nodules), then documented on biopsy with noncaseating epithelioid granuloma or granulomatous reaction in all but one case. In such situations, biopsy is worthwhile in order to distinguishing this phenomenon from progressive stage-4 cancer disease and to not discontinue CPI treatment. Other symptoms include frequent cutaneous manifestations (nodules, rash), cough/dyspnea and arthralgia/arthritis. Uveitis, parotiditis, hypercalcemia and neurological symptoms are rarely reported \[[@kez295-B61], [@kez295-B62]\]. Of note, serum angiotensin I-converting enzyme level might be elevated or normal.

Some patients experienced systemic sclerosis \[[@kez295-B7]\] or scleroderma-like reaction \[[@kez295-B63]\], all presenting with skin thickening but only one with associated recent Raynaud phenomenon. None tested positive for specific autoantibodies.

Subacute cutaneous lupus erythematosus with typical erythematous eruption on trunk and/or limbs are described \[[@kez295-B66]\], as well as systemic lupus erythematosus with high titre of ANA and positivity of either anti-dsDNA or anti-SSA/SSB \[[@kez295-B66], [@kez295-B69]\]. One patient experienced CPI-induced lupus nephritis \[[@kez295-B70]\] and one developed Jaccoud arthropathy \[[@kez295-B71]\].

Differential diagnoses
======================

In the context of advanced cancer, metastases should always be considered as a differential diagnosis of rheumatic irAEs, notably in the case of localized articular symptoms or the lack of improvement with adequate treatment \[[@kez295-B72]\]. Recently, non-malignant resorptive lesions (shoulder, hand and clavicle) and rapid bone loss leading to multiple fractures with vertebral compression have also been described under CPI treatment, making the differential diagnosis with metastases even more challenging and raising the question of the potential influence of immune activation on bone metabolism \[[@kez295-B73]\].

In lung cancer patients, paraneoplastic syndromes such as hypertrophic osteoarthropathy occurring after CPI-onset while not present or asymptomatic at cancer diagnosis have also recently been noticed. Patients usually presented with inflammatory pain in extremities, swollen joints (with non-inflammatory synovial fluid analysis) and nail clubbing. Plain radiographs show periostitis, as illustrated with [Fig. 4](#kez295-F4){ref-type="fig"}.

![Representative image of periostitis in a patient developing hypertrophic osteoarthropathy after CPI onsetCPI: checkpoint inhibitors.](kez295f4){#kez295-F4}

Finally, in case of fatigue and diffuse pain or weakness, central adrenal insufficiency should be suspected as it is a possible immune-related complication of CPI \[[@kez295-B74]\]. The diagnosis can be challenging, confirmed by the low dosage of cortisol and low Adreno CorticoTrophic Hormone. The presence of associated hypotension and hyponatremia may help to suspect an underlying endocrinopathy.

Conclusion
==========

Rheumatic, musculoskeletal and systemic irAEs represent a new clinical entity within the field, as numbers of patients presenting with rheumatic irAE do not fulfil the traditional classification criteria of RMDs. On the other hand, it seems that some patients develop genuine classic RMDs, with possible influence of immunogenetic framework \[[@kez295-B75]\]. Owing to the rapid development and dissemination of CPI therapy, rheumatologists should be aware of the wide spectrum of rheumatic irAEs, with their respective clinical characteristics.
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